{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:38:09Z","timestamp":1775162289531,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>The development of multiple highly effective and safe direct-acting antivirals to treat hepatitis C virus (HCV) has resulted in greater ease and confidence in managing HCV infection in transplant recipients that in turn has impacted the solid organ transplant community as well. In the United States, the opioid epidemic has increased the number of overdose deaths with a concomitant increase in younger HCV viremic donors after brain death being identified. At the same time, a decrease in HCV viremic transplant candidates has led to a growing interest in exploring the use of HCV viremic liver and kidney donor allografts in HCV-negative recipients. To date, experience with the use of HCV viremic liver and kidney allografts in HCV-negative recipients is limited to a few small prospective research trials, case series, and case reports. There are also limited data on recipient and donor selection for HCV viremic liver and kidney allografts. In response to this rapidly changing landscape in the United States, experts in the field of viral hepatitis and liver and kidney transplantation convened a meeting to review current data on liver and kidney recipient selection and developed consensus opinions related specifically to recipient and donor selection of HCV viremic liver and kidney allografts.<\/jats:p>","DOI":"10.1097\/tp.0000000000003014","type":"journal-article","created":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T17:43:27Z","timestamp":1571593407000},"page":"476-481","source":"Crossref","is-referenced-by-count":27,"title":["Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation"],"prefix":"10.1097","volume":"104","author":[{"given":"James R.","family":"Burton","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah A.","family":"Terrault","sequence":"additional","affiliation":[{"name":"Department of Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy D.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gilroy","sequence":"additional","affiliation":[{"name":"Liver Transplant Program, Intermountain Medical Center, Salt Lake City, UT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Heimbach","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic Rochester, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory T.","family":"Everson","sequence":"additional","affiliation":[{"name":"HepQuant, LLC, Greenwood Village, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russ","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic Rochester, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Pomfret","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation.","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial.","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial.","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1111\/ajt.15311","article-title":"Transplanting hepatitis C virus-infected hearts into uninfected recipients: a single-arm trial.","volume":"19","author":"McLean","year":"2019","journal-title":"Am J Transplant"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients.","volume":"380","author":"Woolley","year":"2019","journal-title":"N Engl J Med"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/ajt.15162","article-title":"Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.","volume":"19","author":"Kwong","year":"2019","journal-title":"Am J Transplant"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14787210.2018.1505502","article-title":"Direct-acting antiviral treatment of acute hepatitis C virus infections.","volume":"16","author":"Misra","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/00007890-199610270-00004","article-title":"The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients.","volume":"62","author":"Cosio","year":"1996","journal-title":"Transplantation"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1681\/ASN.2015050478","article-title":"Tubuloreticular inclusions in renal allografts associate with viral infections and donor-specific antibodies.","volume":"27","author":"Willicombe","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/01.ASN.0000012382.97168.E0","article-title":"Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus.","volume":"13","author":"Bloom","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1111\/j.1600-6143.2009.02843.x","article-title":"Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients.","volume":"9","author":"Baid-Agrawal","year":"2009","journal-title":"Am J Transplant"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cgh.2017.06.024","article-title":"Cost effectiveness of pre- vs post-liver transplant hepatitis C treatment with direct-acting antivirals.","volume":"16","author":"Samur","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R13-20231002","first-page":"513","article-title":"Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic--Nevada, 2007.","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cld.2009.11.006","article-title":"Health care-associated transmission of hepatitis B and C in oncology care.","volume":"14","author":"Stevens","year":"2010","journal-title":"Clin Liver Dis"},{"key":"R15-20231002","first-page":"101","article-title":"Outbreak of hepatitis C virus infections at an outpatient hemodialysis facility: the importance of infection control competencies.","volume":"40","author":"Rao","year":"2013","journal-title":"Nephrol Nurs J"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1034\/j.1600-6143.2001.10213.x","article-title":"Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival.","volume":"1","author":"Batty","year":"2001","journal-title":"Am J Transplant"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TP.0000000000002096","article-title":"Impact of willingness to accept hepatitis C seropositive kidneys among hepatitis C RNA-positive waitlisted patients.","volume":"102","author":"Sageshima","year":"2018","journal-title":"Transplantation"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2018.11.009","article-title":"Mortality and kidney transplantation outcomes among hepatitis C virus-seropositive maintenance dialysis patients: a retrospective cohort study.","volume":"73","author":"Sawinski","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1046\/j.1600-6143.2004.00606.x","article-title":"The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients.","volume":"4","author":"Abbott","year":"2004","journal-title":"Am J Transplant"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-6143.2004.00652.x","article-title":"Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list.","volume":"5","author":"Bloom","year":"2005","journal-title":"Am J Transplant"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.15054","article-title":"Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy.","volume":"18","author":"Gupta","year":"2018","journal-title":"Am J Transplant"},{"key":"R23-20231002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018.","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/TP.0000000000002453","article-title":"International Liver Transplantation Society Asian consensus on the management of hepatitis C virus infection in resource limited setting-from noncirrhotic to decompensated disease and after liver transplantation.","volume":"103","author":"Charlton","year":"2019","journal-title":"Transplantation"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.xphs.2018.02.015","article-title":"A phase 1 study to evaluate the effect of crushing, cutting into half, or grinding of glecaprevir\/pibrentasvir tablets on exposures in healthy subjects.","volume":"107","author":"Oberoi","year":"2018","journal-title":"J Pharm Sci"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0897190017731245","article-title":"Treatment of chronic hepatitis C virus infection with crushed ledipasvir\/sofosbuvir administered via a percutaneous endoscopic gastrostomy tube.","volume":"31","author":"Jindracek","year":"2018","journal-title":"J Pharm Pract"},{"key":"R27-20231002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"},{"key":"R28-20231002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"key":"R29-20231002","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml\/min.","volume":"36","author":"Nazario","year":"2016","journal-title":"Liver Int"},{"key":"R30-20231002","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"R31-20231002","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/TP.0000000000002196","article-title":"Reduced access to liver transplantation in women: role of height, MELD exception scores, and renal function underestimation.","volume":"102","author":"Allen","year":"2018","journal-title":"Transplantation"},{"key":"R32-20231002","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.29219","article-title":"Development of a novel frailty index to predict mortality in patients with end-stage liver disease.","volume":"66","author":"Lai","year":"2017","journal-title":"Hepatology"},{"key":"R33-20231002","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jhep.2017.11.030","article-title":"A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort.","volume":"68","author":"van Vugt","year":"2018","journal-title":"J Hepatol"},{"key":"R34-20231002","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/TP.0000000000002467","article-title":"The effect of the opioid epidemic on donation after circulatory death transplantation outcomes.","volume":"103","author":"Wanis","year":"2019","journal-title":"Transplantation"},{"key":"R35-20231002","doi-asserted-by":"crossref","first-page":"100","DOI":"10.12669\/pjms.341.14361","article-title":"Liver histology in asymptomatic hepatitis-C virus positive blood donors.","volume":"34","author":"Anwar","year":"2018","journal-title":"Pak J Med Sci"},{"key":"R36-20231002","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3109\/00365521.2012.672592","article-title":"Impact of donor histology on survival following liver transplantation for chronic hepatitis C virus infection: a Scandinavian single-center experience.","volume":"47","author":"Ydreborg","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"R37-20231002","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.29557","article-title":"Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.","volume":"67","author":"Mauro","year":"2018","journal-title":"Hepatology"},{"key":"R39-20231002","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cgh.2016.03.040","article-title":"Disparities in absolute denial of modern hepatitis C therapy by type of insurance.","volume":"14","author":"Lo Re","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R40-20231002","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41395-018-0033-8","article-title":"Race\/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.","volume":"113","author":"Wong","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"R41-20231002","first-page":"329","article-title":"Increasing access to hepatitis C virus medications: a program model using patient navigators and specialty pharmacy to obtain prior authorization approval.","volume":"24","author":"Vu","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"R42-20231002","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ajt.15152","article-title":"Transplantation of HCV-infected organs into uninfected recipients: advance with caution.","volume":"19","author":"Wadei","year":"2019","journal-title":"Am J Transplant"},{"key":"R43-20231002","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000495263","article-title":"Use of hepatitis C positive organs: patient attitudes in urban Chicago.","volume":"49","author":"Couri","year":"2019","journal-title":"Am J Nephrol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:10:51Z","timestamp":1696223451000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003014","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}